CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

Description

CJC-1295 NO DAC for sale

Growth hormones help to develop and thereby maintain the body and elevate energy levels. They play a vital role in adults as the regulator of body growth and development, metabolic rate and other key bodily functions such as the cardiovascular system, cognitive functions and enhancing lipid metabolism.

It is common that as the age increases, the levels of these hormones start declining. Interestingly, after the age of 30 years, the hormonal level decreases by 14% every 10 years (1). Furthermore, disorders such as growth hormone deficiency (GHD) lead to decreased concentrations of growth hormones, which further decrease the ability of the body to perform usual functions.

To combat such adverse conditions, there are some peptide compounds available – mainly belonging to the class of Growth Hormone Releasing Hormones (GHRH) – that help stimulate the secretion of growth hormones in the body and maintain its equilibrium. One of the peptides belonging to this GHS family is CJC-1295 (no DAC).

Introduction to CJC-1295 NO DAC Peptide

Growth hormone releasing hormones are naturally synthesized and produced in our body, however, with increasing age, the levels of these hormones start to naturally decline.

CJC 1295 is a synthetic peptide derivative of the naturally occurring GHRH hormones and is composed of 29 amino acids (2). This peptide is also referred to as DAC GRF (i.e., Drug Affinity Complex Growth hormone Releasing Factor).

CJC-1295 NO DAC, also sometimes called Modified GRF (1-29) or CJC 1295 without DAC, is a modified version of the peptide containing four substituted amino groups that help prevent its degradation and thereby prolong its longevity and effects in the human body.

Discovery Timelines

Modified growth hormone fragments GRF (1-29) were first discovered in the early 1980s where it was noted that the first 29 amino acids of the natural growth hormone releasing hormone retained all the properties of the full 44 amino acid peptide (3).

One of the major drawbacks with synthesized growth hormone releasing peptides is their short half-life, which leads to short term effects only. Rigorous research since then led to the discovery of a stabilized, longer lasting CJC 1295 (No DAC) peptide (4).

Working Mechanism of CJC-1295 NO DAC Peptide

CJC-1295 NO DAC peptide augments the production of the growth hormone by binding to the serum albumin present in the body via a free thiol group and forming a covalent disulfide bond (5).

This triggers a small part of the pituitary gland which then releases higher concentrations of growth hormone naturally in the body, thereby helping to maintain the required equilibrium in the body.

Given that this peptide also possesses four amino acid substitutions in its structure, it has enhanced bioactivity and resistance towards the proteolytic enzymes. The peptide is not only able to bind covalently to albumin but can also have trace amounts bound to fibrinogen and immunoglobulin G (IgG) (4). This event leads to elevated levels of plasma growth hormone as well as insulin-like growth factor 1, or IGF-1.

Significance of CJC-1295 NO DAC Peptide

The various benefits of CJC-1295 NO DAC peptide include:

• Increased bone density
• Enhanced lean muscle mass
• Improved ability to burn excess fat
• Increased recovery rate from injuries
• Enhanced insulin sensitivity
• Increased energy levels
• Potential role in combating intestinal problems
• Potential therapeutic agent to improve heart rate

Research and Clinical Studies

Clinical Studies Associated With GHSs and GHRHs

In this study (6), the safety and efficacy of the growth hormone secretagogues (GHS) and growth hormone releasing hormones (GHRH) – the class of hormones to which the peptide belongs – in the human volunteers was studied. Several analogues were administered to the human subjects, who were then monitored for any physiological changes.

As an outcome of this long lasting, rigorous study, it was determined that these hormones led to improved growth velocity, stimulate human appetite, and improve lean mass in adults. In obese subjects, these peptides stimulated reduction in bone turnover, increased lean mass and improved sleep cycle.

This study concluded that the peptide was well tolerated in humans, demonstrating high efficiency and potency.

Clinical Studies Associated With the CJC Peptide

Single dose study

In the early 2000s study (7), a clinical trial was conducted on healthy male volunteers aged between 20 and 40 years of age. Volunteers were divided into two groups – one was administered with the placebo and the other group with the peptide. Blood was sampled out from the volunteers one week before and after the administration of CJC 1295 peptide (or placebo) to monitor the levels of growth hormone pulsatility. CJC 1295 peptide was administered in doses of either 60 or 90 micro/kg of body weight.

At the end of the study, it was found that CJC 1295 led to a 7.5-fold increase in the growth hormone pulsatility levels as compared to that of the placebo. These levels increased gradually through the period of the dose administration and remained unaltered even after one week of the drug administration.

This study thus concluded that a single dose of CJC 1295 peptide had a long-lasting effect up to at least one week without any reported side effects.

Multi-dose study

Healthy candidates aged between 21 and 61 years of age participated in the two-double blind, ascending dose trials (8) with a period of 28 days. Candidates were divided into two groups; one group was administered with either 30 or 60 microg/kg per body weight of CJC 1295 without DAC peptide, and the other with placebo.

All doses were administered subcutaneously in four ascending doses in the first study (ascending dose) and in two or three doses weekly or biweekly in the second study (increasing frequency).

At the end of the first study, it was determined that there was a dose dependent increment in the mean plasma growth hormone level by up to 10 folds for more than 6 days and in the levels of IGF-1 concentrations by up to 3 folds for up to 11 days. In the second study, it was determined that with multiple doses of the peptide, the mean levels of the growth hormone and IGF-1 remained above baseline for up to 28 days. There were no adverse events reported.

This study concluded that CJC-1295 NO DAC is a highly tolerable peptide with longer lasting effect, of up to 8 days if given in single dose and up to 28 days if given in multiple doses.

Intestinal studies

Early research on growth hormones suggested that they had positive effects on common intestinal disorders such as short bowel syndrome and inflammatory bowel ailments. Interestingly, these benefits were outweighed by the risks associated with the exogenous administration of the growth hormones. Thus, the scientists have been researching if analogues of these hormone peptides (eg., GHRH analogues like CJC 1295 peptide) can instead provide long lasting effects.

Studies (9) were conducted in monkeys which have shown that the GHRH analog peptides interact with the VPAC(1)-R – found on the smooth muscles of the gastrointestinal system in the body. This led to several positive effects including improved bowel movement, which is of significant importance in inflammatory bowel disease and constipation. Hence, there are some positive effects of the peptide on the intestine, however, more clinical studies are yet to be conducted to confirm the same in humans.

Improved Heart Rate

While clinical studies are yet to be conducted, preliminary research (10) in rodents suggest that modified GRF 1-29 peptide (along with other GHRH derivative analogs) have the potential to improve the heart rate and its ability to pump blood, following a heart attack. These NIH studies (10) also state that GHRH agonist peptides promote cardiac tissue repair and improve ejection fraction rates.

This suggests that the peptide may have long term clinical benefits, however, studies are yet to be completed to confirm these results.

Studies Demonstrating Relation Between Thyroid and Growth Hormones

It is a known fact that any problems with the thyroid gland (such as hypothyroidism) often associate with impairment in growth hormone production and release in the body.

In order to further probe this relationship, researchers conducted a study (11) in patients suffering from primary hypothyroidism before and after thyroid replacement surgery.

Fourteen patients aged between 26 and 60 years were subjected to Modified GRF peptides before and after replacement therapy. After the study, the levels of growth hormones were monitored in these patients.

Results demonstrated that patients responded more efficiently to GRF peptide after thyroid replacement than before. These results provide a better picture of the human body physiology suggesting that thyroid replacement surgery enhances responsiveness of the somatotroph to the GRF treated patients.

Side Effects of CJC-1295 NO DAC Peptide

Based on the clinical studies conducted so far on the human volunteers, it has been determined that Modified GRF 1-29 is a well-tolerated peptide, with minimal side effects.

Some of the common peptide side effects include:

• Pain, and temporary discomfort at the site of injection
• Nausea
• Lightheadedness
• Flu like symptoms
• Fatigue

Common CJC 1295 Peptide Combinations

CJC-1295 NO DAC is a longer lasting GHRH analogue compared to other synthetic GHRH (and GHS) peptides. Consequently, when combined with other short acting peptides, it helps elevate the effects for a longer duration.

One such highly common peptide combination is with Ipamorelin, a synthetic GHRH pentapeptide.

Both Ipamorelin and CJC peptides have similar modes of actions whereby both peptides act on the anterior pituitary gland and stimulate growth hormone secretion in the body. When the peptide blend is administered to the body, the Ipamorelin peptide kicks in first.

It starts producing effects for up to the first two hours (12) of administration, and as it starts to wean off, the benefits of the CJC 1295 peptide gradually start coming into play. The effects of the single dose peptide blend last up to 10 days (4).

Summary

CJC-1295 NO DAC, also referred to as Mod GRF (1-29), and CJC 1295 without DAC, is a modified version of the naturally occurring GHRH hormone peptide composed of 29 amino acids. It possesses four substituted amino groups, which help prevent its degradation and thereby prolong its longevity and effects in the human body.

The peptide primarily functions by triggering a small part of the anterior pituitary gland which then stimulates the secretion of the growth hormones in the body. Clinical studies in human volunteers have demonstrated the longevity and high potency of the peptide in regard to improved lean muscle mass and combating growth hormone deficiency. Preliminary studies in animals also show promising results of the peptide in treating heart and intestine related disorders.

As with other growth hormone analogs, CJC-1295 NO DAC is also banned from sports by WADA and is included in their latest Prohibited List (13). Research continues to date to fully explore and determine the peptide effects in the human body as a potent therapeutic agent.

References:

1. A Giustina, JD Veldhius, Pathophysiology of the neuro regulation of growth hormone secretion in experimental animals and the human, Endocrinology, 1 December 1998, https://europepmc.org/article/med/9861545

2. National Center for Biotechnology Information. “PubChem Compound Summary for CID 91976842, CJC1295 Without DAC” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC

3. Clark, R G, and I C Robinson. “Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats.” Nature vol. 314,6008 (1985): 281-3. https://pubmed.ncbi.nlm.nih.gov/2858818/

4. The Discovery of Growth Hormone-Releasing Hormone: An Update https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01740.x

5. Sackmann-Sala, Lucila et al. “Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.” Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society vol. 19,6 (2009): 471-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787983/

6. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/

7. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/

8. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/

9. Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. https://pubmed.ncbi.nlm.nih.gov/11445245/

10. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. https://pubmed.ncbi.nlm.nih.gov/31070727/

11. Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. https://pubmed.ncbi.nlm.nih.gov/3098458/

12. Gobburu JV, Agersø H, Jusko WJ, Ynddal L (September 1999). “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers”. Pharmaceutical Research. 16 (9): 1412–6. doi:10.1023/A:1018955126402 https://en.wikipedia.org/wiki/Ipamorelin#cite_note-GobburuAgers%C3%B81999-1

13. List of all prohibited substances by WADA – https://www.wada-ama.org/en/

---

 

NOTE: These products are intended for laboratory research use only. CJC-1295 NO DAC / MOD GRF 1 29 peptide is not intended for personal use. Please review our Terms and Conditions before ordering.